Nurix Therapeutics, Inc. (NRIX)
NasdaqGM
Price as at 30 Sept 2026, 21:53 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Nurix Therapeutics, Inc. trades at $23.71. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Super investor ownership
8 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Cathie Wood, ARK Investment Management LLC$43.50M · 0.3% of book
- Ken Griffin, CITADEL ADVISORS LLC$35.83M · 0.0% of book
- Arrowstreet Capital, ARROWSTREET CAPITAL, LIMITED PARTNERSHIP$11.58M · 0.0% of book
- Ken Fisher, Fisher Asset Management, LLC$8.96M · 0.0% of book
- D. E. Shaw, D. E. Shaw & Co., Inc.$4.48M · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Common questions
Which funds own NRIX?
8 of the institutions we track reported a position in NRIX in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
Where does SteadyShares get its NRIX data?
Fundamentals for NRIX come from company filings and exchange data, as listed on NasdaqGM; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 30 Sept 2026, 21:53 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for NRIX, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.